RSS

EPM News

FDA grants fast track designation for Iclaprim

The Food and Drug Administration (FDA) has granted fast track designation for Motif Bio’ iclaprim intravenous (IV) drug to treat acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP) more »

Sep 9, 2015 3:56 PM News

Built with Metro Publisher™